Description

Overview

SS-31, also known as elamipretide (MTP-131), is a mitochondria-targeted synthetic tetrapeptide studied for disorders involving mitochondrial dysfunction. It has been investigated for mitochondrial function, cellular energy production, and tissue protection.

Potential Benefits Under Research

Elamipretide has been studied for:

• Mitochondrial function and cellular energy
• Oxidative-stress pathways
• Muscle and mitochondrial disorders
• Cardiovascular and tissue-function research
• Neurobiological and metabolic research

These effects depend on the specific disease and should not be generalized to healthy individuals.

How It Works

SS-31 targets mitochondria and interacts with cardiolipin, a lipid important for mitochondrial membrane structure and function. Research has focused on whether this can improve mitochondrial energy processes and reduce cellular stress.

Strength

SS-31 10 mg

The 10 mg designation represents the stated quantity of peptide. It is not a universally established human dose. Clinical studies have used different dosing regimens depending on the disease being investigated.

Regulatory Status

An important distinction: elamipretide is now an FDA-approved drug in a specific setting. FDA approved Forzinity (elamipretide) on September 19, 2025, for improving muscle strength in adults and children weighing at least 30 kg with Barth syndrome.

That approval does not mean a generic “SS-31 10 mg” research product is an FDA-approved equivalent. FDA has also issued warning letters concerning marketed SS-31 products described as unapproved new drugs.

Safety

Safety depends on the formulation and medical indication. Clinical development has involved monitoring for adverse effects, and the safety profile of an unapproved research formulation cannot be assumed to match FDA-approved Forzinity.

Conclusion

SS-31 10 mg (elamipretide) is a mitochondria-targeted peptide with substantial clinical research history. Unlike many experimental peptides, elamipretide has an FDA-approved formulation for Barth syndrome, while a standalone 10 mg SS-31 research product should not be represented as an FDA-approved medicine or validated general-purpose treatment.